Status:

COMPLETED

Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study

Lead Sponsor:

The Cooper Health System

Conditions:

Sedation

Flexible Bronchoscopy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To determine safety and effectiveness of dexmedetomidine when administered for conscious sedation during flexible bronchoscopy (FB) in patients with Chronic Obstructive pulmonary Disease (COPD).

Detailed Description

This is a pilot study designed to provide preliminary data on the use of dexmedetomidine for outpatient FB procedures requiring sedation. Clinical parameters such as vital signs, level of sedation, do...

Eligibility Criteria

Inclusion

  • Subject has COPD
  • Subject is ≥ 18 years of age
  • If female, subject is non-lactating and either not able to become pregnant or proven not to be pregnant and actively practicing birth control
  • Subject or subject's legally authorized representative has voluntarily signed and dated an informed consent after all has been explained and any/all questions answered

Exclusion

  • Subject for whom α2 agonists are contraindicated
  • Subject for whom opiates, benzodiazepines, or dexmedetomidine are contraindicated or who has known or suspected serious allergy to any drug that might be administered during the course of the study
  • Subject meets any of the following cardiovascular criteria:
  • (A routine EKG will be performed for potential subjects prior to enrollment in order to screen for unrecognized conduction abnormalities.)
  • Acute unstable angina (defined during current hospital stay)
  • Myocardial infarction within 6 weeks of bronchoscopy
  • Suspicion of acute myocardial infarction
  • Known severe left ventricular failure
  • Heart rate \< 50 bpm prior to infusion start
  • Systolic blood pressure less than 90 mmHg prior to infusion start
  • Conduction abnormalities except 1st degree AV block and rate-controlled atrial fibrillation; subjects with functional pacemaker capacity can be enrolled
  • Known severe liver disease
  • Subject requires dialysis (e.g., hemodialysis, peritoneal dialysis, CVVHD)
  • Subject has a known, uncontrolled seizure disorder
  • Subject on α-agonists or blockers

Key Trial Info

Start Date :

November 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2007

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00401206

Start Date

November 1 2006

End Date

June 1 2007

Last Update

November 5 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cooper University Hospital

Camden, New Jersey, United States, 08103